In this article

MTSR

NOVO.B-DK

PFE

Follow your favorite stocks CREATE FREE ACCOUNT

Pfizer on Monday said it filed a second lawsuit against Novo Nordisk and Metsera , alleging that the Danish drugmaker's attempt to outbid Pfizer to acquire the obesity biotech is anticompetitive.

Pfizer alleges that Ozempic maker Novo Nordisk's proposed acquisition of Metsera would help it maintain its dominant position in the blockbuster obesity market by eliminating a smaller potential competitor, according to the lawsuit filed Monday in the U.S. District Court in Delaware. The suit also alleges that Metsera's controlling shareholders conspired with the obesity biotech and Novo Nordisk.

In a statement on Monday, Ambre James Brown, Novo Nordisk's vice president of

See Full Page